Median survival of Tet-deficient animal models
| Type of malignancy . | Median survival, mo . | Reference . |
|---|---|---|
| Myeloid and lymphoid | ||
| Tet2−/− | 12-18 | 46,51,59 |
| Tet2−/− | >24 | Unpublished (A.R.) |
| Myeloid | ||
| Tet2fl/flTet3fl/fl (CreERT2; acute deletion) | 1 | 115 |
| Tet1fl/flTet2fl/flTet3fl/fl (CreERT2; acute deletion) | 1 | Unpublished (A.R.) |
| Tet2−/−Dnmt3a−/− | 5 | 23 |
| Tet2−/−Jak2V617F | 6 | 116 |
| Tet2−/−AML1-ETO | 6 | 117 |
| Tet2−/−Ncstn−/− | 6 | 118 |
| Tet2−/−NrasG12D | 9-12 | 119 |
| Tet2−/−FLT3ITD | 9-12 | 27 |
| T cell | ||
| Tet2fl/flTet3fl/fl (CD4-Cre) | 2 | 50 |
| Tet2−/−RhoaG17V (T-cell transfer) | 5 | 53 |
| Tet2fl/flRhoaG17V (Cd4-CreERT2 inducible) | 6 | 54 |
| Tet2fl/fl (Vav-Cre) Cd4-RhoaG17V (transgene) | 7 | 55 |
| B cell | ||
| Tet2fl/flCd19-Cre | 16 | 60 |
| Tet1−/− | 22 | 45 |
| Tet1−/−Tet2−/− | 20 | 59 |
| Type of malignancy . | Median survival, mo . | Reference . |
|---|---|---|
| Myeloid and lymphoid | ||
| Tet2−/− | 12-18 | 46,51,59 |
| Tet2−/− | >24 | Unpublished (A.R.) |
| Myeloid | ||
| Tet2fl/flTet3fl/fl (CreERT2; acute deletion) | 1 | 115 |
| Tet1fl/flTet2fl/flTet3fl/fl (CreERT2; acute deletion) | 1 | Unpublished (A.R.) |
| Tet2−/−Dnmt3a−/− | 5 | 23 |
| Tet2−/−Jak2V617F | 6 | 116 |
| Tet2−/−AML1-ETO | 6 | 117 |
| Tet2−/−Ncstn−/− | 6 | 118 |
| Tet2−/−NrasG12D | 9-12 | 119 |
| Tet2−/−FLT3ITD | 9-12 | 27 |
| T cell | ||
| Tet2fl/flTet3fl/fl (CD4-Cre) | 2 | 50 |
| Tet2−/−RhoaG17V (T-cell transfer) | 5 | 53 |
| Tet2fl/flRhoaG17V (Cd4-CreERT2 inducible) | 6 | 54 |
| Tet2fl/fl (Vav-Cre) Cd4-RhoaG17V (transgene) | 7 | 55 |
| B cell | ||
| Tet2fl/flCd19-Cre | 16 | 60 |
| Tet1−/− | 22 | 45 |
| Tet1−/−Tet2−/− | 20 | 59 |